CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - A mirna microarray analysis

Genes Chromosomes and Cancer

Volumn 48, Issue 7, 2009, Pages 615-623

  Guled, Mohamed ^a   Lahti, Leo ^a,b   Lindholm, Pamela M ^a   Salmenkivi, Kaisa ^a   Bagwan, Izhar ^c   Nicholson, Andrew G ^c   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA;

ADULT; AGED; ARTICLE; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 8Q; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HGF GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JUN GENE; MALE; MALIGNANT MESOTHELIOMA; MICROARRAY ANALYSIS; NF2 GENE; OCCUPATIONAL EXPOSURE; ONCOGENE; PDGA GENE; PRIORITY JOURNAL; RISK FACTOR; RNA ANALYSIS; SMOKING; SURVIVAL RATE;

AGED; ASBESTOS; CHROMOSOMES, HUMAN; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; NEUROFIBROMIN 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-JUN; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 67449086733     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20669     Document Type: Article

References (48)

1. Addis B, Roche H. 2009. Problems in mesothelioma diagnosis. Histopathology 54:55-68.
2. Ambras V. 2004. The functions of animal microRNAs. Nature 431:350-355. (Pubitemid 39265675)
3. Angel P, Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129-157. (Pubitemid 121007534)
4. Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, Jhanwar SC, Testa JR. 1999. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59:450-454.
5. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297. (Pubitemid 38167318)
6. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. 1997. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75:523-527. (Pubitemid 27085293)
7. Bjorkqvist AM, Wolf M, Nordling S, Tammilehto L, Knuuttila A, Kere J, Mattson K, Knuutila S. 1999. Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 81:1111-1115.
8. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529. (Pubitemid 35403967)
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999-3004.
10. Carbone M, Kratzke RA, Testa JR. 2002. The pathogenesis of mesothelioma. Semin Oncol 29:2-17. (Pubitemid 34163530)
11. Christensen BC, Godleski JJ, Roelofs CR, Longacker JL, Bueno R, Sugarbaker DJ, Marsit CJ, Nelson HH, Kelsey KT. 2008. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect 116:723-726. (Pubitemid 351943926)
12. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. 2000. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13:107-112. (Pubitemid 30109095)
13. De Rienzo A, Jhanwar SC, Testa JR. 2000. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 28:337-341. (Pubitemid 30399564)
14. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA. 2007. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther 7:1009-1019.
15. Fabbri M, Croce CM, Calin GA. 2008. MicroRNAs. Cancer J 14:1-6.
16. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE, Litle VR. 2008. MicroRNA expression profiles of esophageal cancer. J Thorac Oardiovasc Surg 135:255-260.
17. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V. 2007. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2:957-965. (Pubitemid 47511601)
18. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. 2008. miRBase: Tools for microRNA genomics. Nucleic Acids Res 36:D154-D158. (Pubitemid 351149713)
19. Hwang HW, Mendell JT. 2006. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94:776-780.
20. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070.
21. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. 2008. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 124:589-599.
22. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberci R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. 2006. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66:352-361. (Pubitemid 43166042)
23. Kivipensas P, Bjorkqvist AM, Karhu R, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Kallioniemi QP, Knuutila S. 1996. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89:7-13.
24. Krismann M, Muller KM, Jaworska M, Johnen G. 2002. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 197:363-371. (Pubitemid 34778307)
25. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, Murphy SE, Yang P, Pesatori AC, Consonni D, Bertazzi PA, Wacholder S, Shih JH, Caporaso NE, Jen J. 2008. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 3:e1651.
26. Lewis BP, Burge CB, Barrel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20. (Pubitemid 40094598)
27. Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, Kinnula VL, Knuutila S. 2007. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 119:46-52.
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838. (Pubitemid 40839735)
29. Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, Shyr Y, Spitz MR. 2008. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Grit Care Med 178:1164-1172.
30. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. 2001. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 24:694-702. (Pubitemid 32550591)
31. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1:882-891. (Pubitemid 37288707)
32. Mossman BT, Gee JB. 1989. Asbestos-related diseases. N Engl J Med 320:1721-1730. (Pubitemid 19163128)
33. Mossmàn BT, Bignon J, Corn M, Seaton A, Gee JB. 1990. Asbestos: Scientific developments and implications for public policy. Science 247:294-301. (Pubitemid 20046453)
34. Mossman BT, Kamp DW, Weitzman SA. 1996. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 14:466-480. (Pubitemid 26338211)
35. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. 2008. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:2690-2695.
36. Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S. 2004. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10:849-859. (Pubitemid 38198883)
37. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Tesra JR. 2006. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25:5960-5968. (Pubitemid 44477290)
38. Robinson BW, Lake RA. 2005. Advances in malignant mesothelioma. N Engl J Med 353:1591-1603.
39. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231.
40. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445. (Pubitemid 37033947)
41. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y. 2007. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438-446. (Pubitemid 46195618)
42. Tiainen M, Tammilehto L, Mattson K, Knuutila S. 1988. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 33:251-274. (Pubitemid 18187785)
43. Toyooka S, Kishimoto T, Date H. 2008. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama 62:1-7.
44. Travis WD, Brambilla E, Müller-Hermelink, Harris CC, editors. 2004. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
45. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261. (Pubitemid 43271657)
46. Wagner JC, Sleggs CA, Marchand P. 1960. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260-271.
47. Wang H, Ach RA, Curry B. 2007. Direct and sensitive miRNA profiling from low-input ratal RNA. RNA 13:151-159. (Pubitemid 46026189)
48. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198. (Pubitemid 43357945)